BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23723112)

  • 1. Established and forthcoming drugs for the treatment of osteoporosis.
    Lems WF; den Heijer M
    Neth J Med; 2013 May; 71(4):188-93. PubMed ID: 23723112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established and forthcoming drugs for the treatment of osteoporosis.
    Lems WF; Geusens P
    Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
    Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
    MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of osteoporosis with parathyroid hormone and teriparatide.
    Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
    Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
    Pazianas M; Abrahamsen B
    Ann N Y Acad Sci; 2016 Jul; 1376(1):5-13. PubMed ID: 27525578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on osteoporosis therapies.
    Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
    J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S
    Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future treatments of osteoporosis in men.
    Kaufman JM; Lapauw B; Goemaere S
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):871-84. PubMed ID: 25432358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
    Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
    Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy in the treatment of osteoporosis.
    Boonen S; Milisen K; Gielen E; Vanderschueren D
    Curr Med Res Opin; 2011 Jun; 27(6):1149-55. PubMed ID: 21466276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.